JLJimmy Lee

Jimmy Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jimmy Lee has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drawn‐on‐Skin Sensors from Fully Biocompatible Inks toward High‐Quality Electrophysiology

    by Shubham Patel, Faheem Ershad, Jimmy Lee, Lourdes Chacon‐Alberty, Yifan Wang, Marco A. Morales‐Garza, Arturo Haces‐Garcia, Seonmin Jang, Lei Gonzalez, Luis Contreras, et al.

    The need to develop wearable devices for personal health monitoring, diagnostics, and therapy has inspired the production of innovative on‐demand, customizable technologies. Several of these technologies enable printing of raw electronic materials directly onto biological organs and tissues. However, few of them have been thoroughly investigated for biocompatibility of the raw materials on the cellular, tissue, and organ levels or with different cell types. In addition, highly accurate multiday in vivo monitoring using such on‐demand, in situ fabricated devices has yet to be done. Presented herein is the first fully biocompatible, on‐skin fabricated electronics for multiple cell types and tissues that can capture electrophysiological signals with high fidelity. While also demonstrating improved mechanical and electrical properties, the drawn‐on‐skin ink retains its properties under various writing conditions, which minimizes the variation in electrical performance. Furthermore, the drawn‐on‐skin ink shows excellent biocompatibility with cardiomyocytes, neurons, mice skin tissue, and human skin. The high signal‐to‐noise ratios of the electrophysiological signals recorded with the DoS sensor over multiple days demonstrate its potential for personalized, long‐term, and accurate electrophysiological health monitoring.


  • N6‐methyladenosine modification of lncRNA Pvt1 governs epidermal stemness

    by Jimmy Lee, Yuchen Wu, Bryan T Harada, Yuanyuan Li, Jing Zhao, Chuan He, Yanlei Ma, Xiaoyang Wu

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Top Cited Papers
    Open Access

    A pulsatile release platform based on photo-induced imine-crosslinking hydrogel promotes scarless wound healing

    by Jian Zhang, Yongjun Zheng, Jimmy Lee, Jieyu Hua, Shilong Li, Ananth Panchamukhi, Jiping Yue, Xuewen Gou, Zhaofan Xia, Linyong Zhu, et al.

    Effective healing of skin wounds is essential for our survival. Although skin has strong regenerative potential, dysfunctional and disfiguring scars can result from aberrant wound repair. Skin scarring involves excessive deposition and misalignment of ECM (extracellular matrix), increased cellularity, and chronic inflammation. Transforming growth factor-β (TGFβ) signaling exerts pleiotropic effects on wound healing by regulating cell proliferation, migration, ECM production, and the immune response. Although blocking TGFβ signaling can reduce tissue fibrosis and scarring, systemic inhibition of TGFβ can lead to significant side effects and inhibit wound re-epithelization. In this study, we develop a wound dressing material based on an integrated photo-crosslinking strategy and a microcapsule platform with pulsatile release of TGF-β inhibitor to achieve spatiotemporal specificity for skin wounds. The material enhances skin wound closure while effectively suppressing scar formation in murine skin wounds and large animal preclinical models. Our study presents a strategy for scarless wound repair.


  • PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma

    by Wei-Ge Wang, Xiang-Nan Jiang, Dong Sheng, Chen-Bo Sun, Jimmy Lee, Xiao-Yan Zhou, Xiao-Qiu Li


  • XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

    by Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, et al.

    Inhibition of B-cell receptor (BCR) signaling through the BTK inhibitor, ibrutinib, has generated a remarkable response in mantle cell lymphoma (MCL). However, approximately one third of patients do not respond well to the drug, and disease relapse on ibrutinib is nearly universal. Alternative therapeutic strategies aimed to prevent and overcome ibrutinib resistance are needed. We compared and contrasted the effects of selinexor, a selective inhibitor of nuclear export, with ibrutinib in six MCL cell lines that display differential intrinsic sensitivity to ibrutinib. We found that selinexor had a broader antitumor activity in MCL than ibrutinib. MCL cell lines resistant to ibrutinib remained sensitive to selinexor. We showed that selinexor induced apoptosis/cell-cycle arrest and XPO-1 knockdown also retarded cell growth. Furthermore, downregulation of the NFκB gene signature, as opposed to BCR signature, was a common feature that underlies the response of MCL to both selinexor and ibrutinib. Meanwhile, unaltered NFκB was associated with ibrutinib resistance. Mechnistically, selinexor induced nuclear retention of IκB that was accompanied by the reduction of DNA-binding activity of NFκB, suggesting that NFκB is trapped in an inhibitory complex. Coimmunoprecipitation confirmed that p65 of NFκB and IκB were physically associated. In primary MCL tumors, we further demonstrated that the number of cells with IκB nuclear retention was linearly correlated with the degree of apoptosis. Our data highlight the role of NFκB pathway in drug response to ibrutinib and selinexor and show the potential of using selinexor to prevent and overcome intrinsic ibrutinib resistance through NFκB inhibition.


  • Open Access

    Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

    by Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Shengjian Huang, Hui Zhang, Mir Alikhan, et al.

    The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially. To identify the mechanisms underlying primary ibrutinib resistance in MCL, we analyzed the transcriptome changes in ibrutinib-sensitive and ibrutinib-resistant cell lines on ibrutinib treatment. We found that MYC gene signature was suppressed by ibrutinib in sensitive but not resistant cell lines. We demonstrated that MYC gene was structurally abnormal and MYC protein was overexpressed in MCL cells. Further, MYC knockdown with RNA interference inhibited cell growth in ibrutinib-sensitive as well as ibrutinib-resistant cells. We explored the possibility of inhibiting MYC through HSP90 inhibition. The chaperon protein is overexpressed in both cell lines and primary MCL cells from the patients. We demonstrated that MYC is a bona fide client of HSP90 in the context of MCL by both immunoprecipitation and chemical precipitation. Furthermore, inhibition of HSP90 using PU-H71 induced apoptosis and caused cell cycle arrest. PU-H71 also demonstrates strong and relatively specific inhibition of the MYC transcriptional program compared with other oncogenic pathways. In a MCL patient-derived xenograft model, the HSP90 inhibitor retards tumor growth and prolongs survival. Last, we showed that PU-H71 induced apoptosis and downregulated MYC protein in MCL cells derived from patients who were clinically resistant to ibrutinib. In conclusion, MYC activity underlies intrinsic resistance to ibrutinib in MCL. As a client protein of HSP90, MYC can be inhibited via PU-H71 to overcome primary ibrutinib resistance.


  • MYC protein dysregulation is driven by BCR‐PI3K signalling in diffuse large B‐cell lymphoma

    by Wei‐Ge Wang, Ze‐Bing Liu, Xiang‐Nan Jiang, Jimmy Lee, Xiao‐Yan Zhou, Xiao‐Qiu Li

    Aims: MYC overexpression is a common feature of diffuse large B‐cell lymphoma (DLBCL) and is associated with poor prognosis in patients with this neoplasm. We aimed to investigate the underlying mechanisms of MYC dysregulation, as they have not been fully determined.Methods and results: We immunohistochemically evaluated the correlation between B‐cell receptor (BCR)–phosphoinositide 3‐kinase (PI3K) pathway activity and MYC level in 108 cases of de‐novo DLBCL, 25 of which featured loss of BCR, and investigated the effects of BCR–PI3K signalling on MYC level and phosphorylation in DLBCL cell lines. The expression levels of phospho‐SYK and phospho‐AKT correlated with MYC expression in BCR‐positive DLBCL. MYC expression was significantly lower in BCR‐negative tumour tissues than in BCR‐positive tumour tissues. Upon BCR stimulation, the BCR‐positive cell lines showed active BCR–PI3K signalling and decreased MYC phosphorylation at T58, leading to an increased overall level of MYC. Conversely, inhibition of BCR–PI3K signalling increased MYC phosphorylation and thus resulted in a decreased overall level of MYC. No effects were observed in the BCR‐negative cell lines.Conclusions: Overexpression of MYC in DLBCL can be driven by the BCR–PI3K signalling pathway via dephosphorylation at T58, and BCR inhibitors may exert their functions by down‐regulation of MYC.


  • Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

    by Sabah Kadri, Jimmy Lee, Carrie Fitzpatrick, Natalie Galanina, Madina Sukhanova, Girish Venkataraman, Shruti Sharma, Brad Long, Kristin Petras, Megan Theissen, et al.

    Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment options. Mutations in BTK and PLCG2 have emerged as main mechanisms of drug resistance, but not all patients carry these mutations. Further understanding of mechanisms of resistance is urgently needed and will support rational development of new therapeutic strategies. To that end, we characterized the genomic profiles of serial samples from 9 patients with ibrutinib-relapsed disease, including 6 who had Richter transformation. Mutations, indels, copy-number aberrations, and loss of heterozygosity were assessed using next-generation sequencing and single-nucleotide polymorphism array. We found that 18p deletion (del(18p)), together with del(17p)/TP53 mutations, was present in 5 of 9 patients before ibrutinib therapy. In addition to BTKC481, we identified BTKT316A, a structurally novel mutation located in the SH2 domain of BTK. Minor BTK clones with low allele frequencies were captured in addition to major BTK clones. Although TP53 loss predisposes patients for relapse, clone size of TP53 loss may diminish during disease progression while mutant BTK clone expands. In patients who had Richter transformation, we found that the transformed cells were clonal descendants of circulating leukemia cells but continued to undergo evolution and drifts. Surprisingly, transformed lymphoma cells in tissue may acquire a different BTK mutation from that in the CLL leukemia cells. Collectively, these results provide insights into clonal evolution underlying ibrutinib relapse and prompt further investigation on genomic abnormalities that have clinical application potential.